• Explore /
  • Poster
  • / Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).

Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).

Abstract Poster

Authors

null

Jonathan E. Rosenberg

Memorial Sloan Kettering Cancer Center, New York, NY

Jonathan E. Rosenberg , Elisabeth I. Heath , Peter J. Van Veldhuizen , Jaime R. Merchan , Joshua Michael Lang , Joseph D. Ruether , Daniel Peter Petrylak , Randeep S. Sangha , David C. Smith , Srikala S. Sridhar , Elaina M. Gartner , Martha Vincent , Rong Chu , Banmeet Anand , Fernando Donate , Lynnae Jackson , Leonard M. Reyno , Jingsong Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Bladder Cancer

Clinical Trial Registration Number

NCT02091999

Citation

J Clin Oncol 34, 2016 (suppl; abstr 4533)

DOI

10.1200/JCO.2016.34.15_suppl.4533

Abstract #

4533

Poster Bd #

156

Abstract Disclosures

Similar Posters

First Author: Daniel Peter Petrylak

Poster

2024 ASCO Genitourinary Cancers Symposium

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).

First Author: Ding-Wei Ye

First Author: Sara A. Hurvitz

First Author: Daniel Peter Petrylak